Posted by Michael Wonder on 06 Mar 2017
Response to the Grattan Institute Report on medicine prices
6 March 2017 - Medicines Australia does not accept the findings of this latest inaccurate, selective and misleading Grattan Report on medicine prices.
Australia’s Pharmaceutical Benefits Scheme (PBS) is the envy of the world because of its ability to provide universal access to breakthrough innovative medicines and generics at tremendous value for taxpayers and affordable prices for Australians who need them.
Medicines Australia Chief Executive Milton Catelin said the latest Grattan report relies on a tiny sample of medicines that have no correlation to the system wide savings being generated through years of PBS reforms.
